Qin Wenru, Zou Bing, Fan Xinyu, Fan Bingjie, Wang Shijiang, Wang Linlin
Department of Oncology, Weifang Medical University, Weifang, Shandong, People's Republic of China.
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, People's Republic of China.
Cancer Manag Res. 2022 Apr 29;14:1595-1602. doi: 10.2147/CMAR.S362858. eCollection 2022.
The most common pathologic type of thymic carcinoma (TC) is squamous cell carcinoma (SCC). Small cell carcinoma is relatively rare, accounting for approximately 2% to 5% of all thymic tumors. Histologic transformation of TC has not yet been reported. Available treatments for TC patients who progress after first-line therapy are limited, which contributes to their poor prognosis. We reported an extraordinary case of a 66-year-old man who was diagnosed with thymic small cell carcinoma that transformed into SCC after third-line treatment. Surprisingly, the patient had a progression-free survival (PFS) of 25 months and an overall survival (OS) of 10 years on anlotinib as fourth-line therapy. The tolerance was well. Thus, anlotinib may be a safe and promising treatment for TC patients, especially those who undergo histologic transformation.
胸腺癌（TC）最常见的病理类型是鳞状细胞癌（SCC）。小细胞癌相对少见，约占所有胸腺肿瘤的2%至5%。尚未有TC组织学转化的报道。一线治疗后病情进展的TC患者可用的治疗方法有限，这导致了他们预后不良。我们报告了一例特殊病例，一名66岁男性被诊断为胸腺小细胞癌，在三线治疗后转化为SCC。令人惊讶的是，该患者作为四线治疗接受安罗替尼治疗后，无进展生存期（PFS）为25个月，总生存期（OS）为10年。耐受性良好。因此，安罗替尼可能是TC患者，尤其是那些发生组织学转化患者的一种安全且有前景的治疗方法。
